急性缺血性卒中动脉内治疗患者选择:两项随机试验中临床决策工具的开发与验证
基于MR CLEAN试验500例(推导队列)和IMS III试验260例颅内闭塞患者(验证队列),构建序贯logistic回归模型预测动脉内治疗获益。外部验证C统计量为0.69(95%CI 0.64-0.73)和0.73(0.67-0.79),个体预测获益从-2.3%到24.3%不等,工具可帮助区分可能获益与不获益的患者。
要点
- 模型纳入11项基线临床和影像学特征,外部验证C统计量0.69(序贯模型)和0.73(良好功能结局预测)。
- 联合队列中个体平均预测治疗获益范围为-2.3%至24.3%。
- 部分既往亚组分析未显示治疗效应的患者(如无或不良侧支循环)中,个体仍可能预测获益。
核心结论
- 所提出的临床决策工具结合多项基线临床和影像学特征,显示患者间治疗获益存在较大差异,临床上有助于区分可能从动脉内治疗中获益与不获益的急性缺血性卒中个体患者。
研究设计与样本
- 采用多变量回归建模,数据来自两项随机对照临床试验。
- 推导队列为荷兰16家医院的MR CLEAN试验500例患者,验证队列为美国、加拿大、澳大利亚和欧洲58家医院的IMS III试验260例颅内闭塞患者。
- 主要结局为卒中后90天改良Rankin量表(mRS)评分,构建序贯logistic回归模型预测结局和治疗获益,治疗获益定义为有无动脉内治疗时良好功能结局(mRS评分0-2)预测概率之差。
主要发现
- 模型纳入11项基线临床和影像学特征。
- 外部验证C统计量:序贯模型为0.69(95%CI 0.64-0.73),良好功能结局预测为0.73(95%CI 0.67-0.79),提示中等区分能力。
- 联合推导和验证队列中,个体平均预测治疗获益范围为-2.3%至24.3%。
- 部分来自既往亚组分析未发现治疗效应组的个体患者(如无或不良侧支循环者)预测可从动脉内治疗中获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective To improve the selection of patients with acute ischaemic stroke for intra-arterial treatment using a clinical decision tool to predict individual treatment benefit.Design Multivariable regression modelling with data from two randomised controlled clinical trials.Setting 16 hospitals in the Netherlands (derivation cohort) and 58 hospitals in the United States, Canada, Australia, and Europe (validation cohort).Participants 500 patients from the Multicenter Randomised Clinical Trial of Endovascular Treatment for Acute Ischaemic Stroke in the Netherlands trial (derivation cohort) and 260 patients with intracranial occlusion from the Interventional Management of Stroke III trial (validation cohort).Main outcome measures The primary outcome was the modified Rankin Scale (mRS) score at 90 days after stroke. We constructed an ordinal logistic regression model to predict outcome and treatment benefit, defined as the difference between the predicted probability of good functional outcome (mRS score 0-2) with and without intra-arterial treatment.Results 11 baseline clinical and radiological characteristics were included in the model. The externally validated C statistic was 0.69 (95% confidence interval 0.64 to 0.73) for the ordinal model and 0.73 (0.67 to 0.79) for the prediction of good functional outcome, indicating moderate discriminative ability. The mean predicted treatment benefit varied between patients in the combined derivation and validation cohort from -2.3% to 24.3%. There was benefit of intra-arterial treatment predicted for some individual patients from groups in which no treatment effect was found in previous subgroup analyses, such as those with no or poor collaterals.Conclusion The proposed clinical decision tool combines multiple baseline clinical and radiological characteristics and shows large variations in treatment benefit between patients. The tool is clinically useful as it aids in distinguishing between individual patients who may experience benefit from intra-arterial treatment for acute ischaemic stroke and those who will not.Trial registration clinicaltrials.gov NCT00359424 (IMS III) and isrctn.com ISRCTN10888758 (MR CLEAN).
引用
- Venema E, Mulder MJHL, Roozenbeek B, et al. Selection of patients for intra-arterial treatment for acute ischaemic stroke: development and validation of a clinical decision tool in two randomised trials. BMJ. 2017. PMID: 28468840. doi:10.1136/bmj.j1710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。